Alumis (ALMS) Competitors $3.31 -0.09 (-2.65%) Closing price 04:00 PM EasternExtended Trading$3.29 -0.02 (-0.60%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ALMS vs. SION, ANAB, NUVB, TRVI, DAWN, STOK, GHRS, SANA, URGN, and AUTLShould you be buying Alumis stock or one of its competitors? The main competitors of Alumis include Sionna Therapeutics (SION), AnaptysBio (ANAB), Nuvation Bio (NUVB), Trevi Therapeutics (TRVI), Day One Biopharmaceuticals (DAWN), Stoke Therapeutics (STOK), GH Research (GHRS), Sana Biotechnology (SANA), Urogen Pharma (URGN), and Autolus Therapeutics (AUTL). These companies are all part of the "pharmaceutical products" industry. Alumis vs. Its Competitors Sionna Therapeutics AnaptysBio Nuvation Bio Trevi Therapeutics Day One Biopharmaceuticals Stoke Therapeutics GH Research Sana Biotechnology Urogen Pharma Autolus Therapeutics Alumis (NASDAQ:ALMS) and Sionna Therapeutics (NASDAQ:SION) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk and dividends. Which has stronger valuation and earnings, ALMS or SION? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlumisN/AN/A-$294.23MN/AN/ASionna TherapeuticsN/AN/A-$61.69MN/AN/A Does the media prefer ALMS or SION? In the previous week, Sionna Therapeutics had 5 more articles in the media than Alumis. MarketBeat recorded 5 mentions for Sionna Therapeutics and 0 mentions for Alumis. Sionna Therapeutics' average media sentiment score of 1.15 beat Alumis' score of 0.00 indicating that Sionna Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Alumis Neutral Sionna Therapeutics Positive Is ALMS or SION more profitable? Sionna Therapeutics' return on equity of 0.00% beat Alumis' return on equity.Company Net Margins Return on Equity Return on Assets AlumisN/A -406.27% -107.29% Sionna Therapeutics N/A N/A N/A Do analysts recommend ALMS or SION? Alumis presently has a consensus price target of $22.86, suggesting a potential upside of 590.55%. Sionna Therapeutics has a consensus price target of $38.50, suggesting a potential upside of 83.68%. Given Alumis' stronger consensus rating and higher probable upside, equities research analysts clearly believe Alumis is more favorable than Sionna Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alumis 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22Sionna Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummarySionna Therapeutics beats Alumis on 5 of the 9 factors compared between the two stocks. Get Alumis News Delivered to You Automatically Sign up to receive the latest news and ratings for ALMS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALMS vs. The Competition Export to ExcelMetricAlumisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$184.98M$2.92B$5.53B$9.03BDividend YieldN/A2.44%5.24%4.07%P/E RatioN/A20.3027.1920.03Price / SalesN/A251.54414.39108.98Price / CashN/A41.7026.2128.59Price / Book0.607.397.925.55Net Income-$294.23M-$55.04M$3.17B$248.49M7 Day Performance10.33%3.01%2.18%5.37%1 Month Performance-7.80%-0.21%1.25%6.63%1 Year PerformanceN/A4.48%33.90%21.20% Alumis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALMSAlumis2.8797 of 5 stars$3.31-2.6%$22.86+590.5%N/A$184.98MN/A0.00N/AGap DownSIONSionna TherapeuticsN/A$15.05+1.5%$38.50+155.8%N/A$664.01MN/A0.0035Gap UpANABAnaptysBio2.2604 of 5 stars$22.58-3.4%$42.38+87.7%-2.8%$663.25M$91.28M-4.65100NUVBNuvation Bio3.5826 of 5 stars$1.95-1.3%$7.17+268.5%-31.2%$661.81M$7.87M-0.8360TRVITrevi Therapeutics3.2509 of 5 stars$5.61-0.9%$20.29+261.6%+128.5%$659.76MN/A-12.5020DAWNDay One Biopharmaceuticals1.6821 of 5 stars$6.41-1.2%$30.57+377.3%-50.4%$649.21M$131.16M-9.0260Upcoming EarningsSTOKStoke Therapeutics3.985 of 5 stars$11.71-1.1%$23.20+98.1%-12.5%$642.92M$36.56M14.91100GHRSGH Research1.5435 of 5 stars$12.34-0.5%$32.00+159.3%+26.9%$641.53MN/A-15.6110Analyst UpgradeSANASana Biotechnology2.5452 of 5 stars$2.83-1.6%$8.60+204.4%-37.2%$636.98MN/A-3.21380URGNUrogen Pharma4.4473 of 5 stars$13.38+2.1%$32.86+145.6%-15.1%$621.10M$90.40M-4.24200Analyst ForecastAUTLAutolus Therapeutics2.1039 of 5 stars$2.30-0.6%$9.32+306.1%-31.3%$611.86M$10.12M-2.61330 Related Companies and Tools Related Companies SION Alternatives ANAB Alternatives NUVB Alternatives TRVI Alternatives DAWN Alternatives STOK Alternatives GHRS Alternatives SANA Alternatives URGN Alternatives AUTL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALMS) was last updated on 7/7/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alumis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alumis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
